Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE However, no studies have analyzed the number of metastatic lymph nodes in patients with estrogen receptor (ER)-positive cancer. 31327134

2020

Entrez Id: 2099
Gene Symbol: ESR1
ESR1
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE Prospective cohort studies of Cd and breast cancer risk suggest a significant relationship between increased Cd intake and cancer incidence, with more pronounced effects for estrogen receptor α (ERα)-positive breast cancers. 31689473

2020

Entrez Id: 2099
Gene Symbol: ESR1
ESR1
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 AlteredExpression BEFREE Breast cancer (BC) is the most common cancer in women, where hormone receptor-positive (HR+; estrogen receptor and/or progesterone receptor) BC comprises the majority (>50%) and has better prognosis, while a minority (<20%) are triple negative BC (TNBC), which has an aggressive phenotype. 31502168

2020

Entrez Id: 2099
Gene Symbol: ESR1
ESR1
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE Cytotoxic activity was studied over a panel of estrogen-receptor-positive (ER+) and negative (ER-) human cancer cell lines by means of both 2D and 3D cell viability studies. 31655896

2020

Entrez Id: 2099
Gene Symbol: ESR1
ESR1
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE For malignant tumors, the association between ADC and major prognostic factors, including histological grade, nuclear grade and lymph node status, as well as estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2) and proliferation marker protein Ki-67.(Ki-67) status, were evaluated. 31452808

2019

Entrez Id: 2099
Gene Symbol: ESR1
ESR1
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 AlteredExpression BEFREE Cancer cell ER expression is inversely related to MI and thus might affect the clinical staging and assessment of BC. 30915533

2019

Entrez Id: 2099
Gene Symbol: ESR1
ESR1
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE Estrogen receptor (ER) antagonist, tamoxifen has been universally used for the treatment of the ER-positive breast cancer; however, the inevitable emergence of resistance to tamoxifen obstructs the successful treatment of this cancer. 30878502

2019

Entrez Id: 2099
Gene Symbol: ESR1
ESR1
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE We aim here to provide a review of recent findings on dynamic transcriptional events mediated by E2-ER alpha with the anticipation that a better understanding of complex regulatory mechanisms underlying ER actions would be a critical basis for the development of effective prognostic tools for and therapeutic interventions against estrogen target tissue malignancies. 30468654

2019

Entrez Id: 2099
Gene Symbol: ESR1
ESR1
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 GeneticVariation BEFREE Breast cancer is one of the most common malignancies and the leading cause of women's death, most of breast cancers are estrogen receptor-positive (ER<sup>+</sup>) breast cancer which can develop into advanced stage from early stage with treatment resistance. 30616080

2019

Entrez Id: 2099
Gene Symbol: ESR1
ESR1
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE This article traces the strategic application of tamoxifen to treat breast cancer by targeting the estrogen receptor (ER), deploying long-term adjuvant tamoxifen therapy, and becoming the first chemopreventive for any cancer. 30911948

2019

Entrez Id: 2099
Gene Symbol: ESR1
ESR1
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE RNA was extracted from tumor material derived from ER+/HER2- patients receiving adjuvant endocrine treatment for low-risk cancers and was semi-quantified by RT-qPCR with the MammaTyper®. 31307414

2019

Entrez Id: 2099
Gene Symbol: ESR1
ESR1
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE This study aimed to evaluate the prognostic significance of the Oncotype DX recurrence score (RS) in T<sub>1-2</sub>N<sub>1</sub>M<sub>0</sub> estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer based on the prognostic stage in the updated American Joint Commission on Cancer, 8th edition. 30456680

2019

Entrez Id: 2099
Gene Symbol: ESR1
ESR1
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE G Protein-Coupled Estrogen Receptor: A Potential Therapeutic Target in Cancer. 31708873

2019

Entrez Id: 2099
Gene Symbol: ESR1
ESR1
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE The cancer and metastatic lung nodules are estrogen dependent and retain estrogen receptor α (ERα) reactivity, but have decreased levels of progesterone receptor (PR) protein. 30655341

2019

Entrez Id: 2099
Gene Symbol: ESR1
ESR1
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE The study elucidates the effect of ɑ-linolenic acid (ALA) on mitochondrial stress, hypoxic cancer microenvironment, and intervention of cholinergic anti-inflammatory pathway using N-methyl-N-nitrosourea (MNU) induced estrogen receptor (ER+) mammary gland carcinoma and Caenorhabditis elegans model, respectively. 30221357

2019

Entrez Id: 2099
Gene Symbol: ESR1
ESR1
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE Both benign and cancer cases were positive for ER while only the cancer cases were positive for HER2. 30763392

2019

Entrez Id: 2099
Gene Symbol: ESR1
ESR1
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE Patients with HER2<sup>+</sup> and estrogen receptor-positive (ER<sup>+</sup>) cancer are additionally treated with long-term hormone therapy. 30846407

2019

Entrez Id: 2099
Gene Symbol: ESR1
ESR1
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE Our data reveal a non-canonical function of YAP1 and TEAD4 as ERα cofactors in regulating cancer growth, highlighting the potential of YAP/TEAD as possible actionable drug targets for ERα<sup>+</sup> breast cancer. 31303470

2019

Entrez Id: 2099
Gene Symbol: ESR1
ESR1
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE To investigate autophagy regulation in YAP signaling in the context of cancer metastasis, we performed profiling analysis of YAP signaling, YAP subcellular localization, autophagosome formation and cell invasiveness in TNBC cell lines (MDA-MB-231 and Hs 578T) versus estrogen receptor (ER) positive breast cancer cell line MCF7. 31590917

2019

Entrez Id: 2099
Gene Symbol: ESR1
ESR1
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE In this review, we provide an overview of NR-based drug discovery in cancer and related resistance mechanisms, focusing on novel strategies for targeting well-established NR targets, including ERα, the AR, the glucocorticoid receptor, and the progesterone receptor, as well as opportunities to target other NRs that are attracting interest in immuno-oncology, such as liver X receptors, retinoic acid-related orphan receptors, and farnesoid X receptors. 30869771

2019

Entrez Id: 2099
Gene Symbol: ESR1
ESR1
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 GeneticVariation BEFREE While the prevalence of ESR1 mutations in gynecologic malignancies is low, there are significant clinical implications useful in guiding therapeutic approaches for these cancers. 30987772

2019

Entrez Id: 2099
Gene Symbol: ESR1
ESR1
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 AlteredExpression BEFREE Breast cancers that have no expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) are defined as triple negative breast cancers (TNBCs); luminal cancers have different expressions of ER, PR and/or HER2. 31348739

2019

Entrez Id: 2099
Gene Symbol: ESR1
ESR1
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 AlteredExpression BEFREE Estrogen receptor alpha (ERα) activity is associated with increased cancer cell proliferation. 31556460

2019

Entrez Id: 2099
Gene Symbol: ESR1
ESR1
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 AlteredExpression BEFREE In vitro studies revealed the potential of the total sub-classes of the synthesized analogs to show anti-proliferative activity against estrogen receptor-dependent cancer cell lines at IC<sub>50</sub> ranging from 28.23 to 57.13 μM. 30731397

2019

Entrez Id: 2099
Gene Symbol: ESR1
ESR1
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE After adjusting for age, year at BC diagnosis, stage, positive nodes, and hormone therapy, patients with BC who became pregnant after their cancer diagnosis had lower total mortality than did the comparison group (HR = 0.44, 95% CI = 0.23-0.84), including that of estrogen receptor-positive patients (HR = 0.23, 95% CI = 0.07-0.77). 31767794

2019